| Drug General Information |
| Drug ID |
D06JYY
|
| Former ID |
DNC008927
|
| Drug Name |
3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H19NO
|
| Canonical SMILES |
COC1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2C4=CN=CC=C4
|
| InChI |
1S/C23H19NO/c1-25-22-10-8-17(9-11-22)13-21-14-18-5-2-3-6-19(18)15-23(21)20-7-4-12-24-16-20/h2-12,14-16H,13H2,1H3
|
| InChIKey |
GOGQHVZGANJJDF-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 11B1, mitochondrial |
Target Info |
Inhibitor |
[1]
|
|---|
| Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Superpathway of steroid hormone biosynthesis
|
|
Glucocorticoid biosynthesis
|
|
Mineralocorticoid biosynthesis
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
SteroidogenesisPW000015:Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Glucocorticoid biosynthesis
|
|
Endogenous sterolsR-HSA-211981:Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Oxidation by Cytochrome P450
|
|
Metabolism of steroid hormones and vitamin D
|
|
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tamoxifen metabolism
|
|
Tryptophan metabolism
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Vitamin D Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. |
|---|
